Home / Innere Medizin / Onkologie / ESMO 2018: We have effective therapies – now we need to find their right sequence
Alison Birtle, MD

ESMO 2018: We have effective therapies – now we need to find their right sequence

Alison Birtle, MD, of Royal Preston Hospital Lancashire Teaching Hospitals, Preston, UK, shares her insights on ESMO’s developments in prostate cancer.

Interviewpartner:

Redaktion:

Produktion:

Chi KN et al., A Randomized Phase 2 Study of Cabazitaxel (CAB) vs (ABI) Abiraterone or (ENZ) Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer (mCRPC). Abstract #792O

Fizazi K et al., Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. Abstract #791O

Smith MR et al., ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Abstract # LBA30

Parker CC et al., Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476). Abstract #LBA5_PR

De Wit R et al., Pembrolizumab for High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 Trial. Abstract #864O

Petrylak I et al., RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. Abstract # 865PD

LOGIN

Login

Passwort vergessen?